Logo image of PHAR

PHARMING GROUP NV - ADR (PHAR) Stock Overview

NASDAQ:PHAR - US71716E1055 - ADR

14.36 USD
+0.35 (+2.5%)
Last: 9/3/2025, 8:00:01 PM

PHAR Key Statistics, Chart & Performance

Key Statistics
52 Week High17.08
52 Week Low6.73
Market Cap983.87M
Shares68.51M
Float67.57M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.13
PEN/A
Fwd PE2319.25
Earnings (Next)11-06 2025-11-06
IPO07-02 1998-07-02
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


PHAR short term performance overview.The bars show the price performance of PHAR in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 20 40 60

PHAR long term performance overview.The bars show the price performance of PHAR in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60 80 100

The current stock price of PHAR is 14.36 USD. In the past month the price increased by 15.06%. In the past year, price increased by 102.83%.

PHARMING GROUP NV - ADR / PHAR Daily stock chart

PHAR Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20.01 374.26B
AMGN AMGEN INC 13.01 152.81B
GILD GILEAD SCIENCES INC 14.6 140.20B
VRTX VERTEX PHARMACEUTICALS INC 23.41 101.69B
REGN REGENERON PHARMACEUTICALS 12.35 59.76B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 58.65B
ARGX ARGENX SE - ADR 77.89 44.19B
ONC BEONE MEDICINES LTD-ADR 6.78 39.97B
INSM INSMED INC N/A 30.33B
BNTX BIONTECH SE-ADR N/A 24.14B
NTRA NATERA INC N/A 22.99B
BIIB BIOGEN INC 8.85 20.76B

About PHAR

Company Profile

PHAR logo image Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 426 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

Company Info

PHARMING GROUP NV - ADR

Darwinweg 24

Leiden ZUID-HOLLAND 2333 CR NL

CEO: Sijmen de Vries

Employees: 404

PHAR Company Website

PHAR Investor Relations

Phone: 31715247400

PHARMING GROUP NV - ADR / PHAR FAQ

What is the stock price of PHARMING GROUP NV - ADR today?

The current stock price of PHAR is 14.36 USD. The price increased by 2.5% in the last trading session.


What is the ticker symbol for PHARMING GROUP NV - ADR stock?

The exchange symbol of PHARMING GROUP NV - ADR is PHAR and it is listed on the Nasdaq exchange.


On which exchange is PHAR stock listed?

PHAR stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for PHARMING GROUP NV - ADR stock?

14 analysts have analysed PHAR and the average price target is 18.59 USD. This implies a price increase of 29.49% is expected in the next year compared to the current price of 14.36. Check the PHARMING GROUP NV - ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is PHARMING GROUP NV - ADR worth?

PHARMING GROUP NV - ADR (PHAR) has a market capitalization of 983.87M USD. This makes PHAR a Small Cap stock.


How many employees does PHARMING GROUP NV - ADR have?

PHARMING GROUP NV - ADR (PHAR) currently has 404 employees.


What are the support and resistance levels for PHARMING GROUP NV - ADR (PHAR) stock?

PHARMING GROUP NV - ADR (PHAR) has a support level at 12.52. Check the full technical report for a detailed analysis of PHAR support and resistance levels.


Is PHARMING GROUP NV - ADR (PHAR) expected to grow?

The Revenue of PHARMING GROUP NV - ADR (PHAR) is expected to grow by 17.66% in the next year. Check the estimates tab for more information on the PHAR EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy PHARMING GROUP NV - ADR (PHAR) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does PHARMING GROUP NV - ADR (PHAR) stock pay dividends?

PHAR does not pay a dividend.


When does PHARMING GROUP NV - ADR (PHAR) report earnings?

PHARMING GROUP NV - ADR (PHAR) will report earnings on 2025-11-06.


What is the Price/Earnings (PE) ratio of PHARMING GROUP NV - ADR (PHAR)?

PHARMING GROUP NV - ADR (PHAR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.13).


What is the Short Interest ratio of PHARMING GROUP NV - ADR (PHAR) stock?

The outstanding short interest for PHARMING GROUP NV - ADR (PHAR) is 0% of its float. Check the ownership tab for more information on the PHAR short interest.


PHAR Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to PHAR. When comparing the yearly performance of all stocks, PHAR is one of the better performing stocks in the market, outperforming 93.63% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

PHAR Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to PHAR. Both the profitability and the financial health of PHAR get a neutral evaluation. Nothing too spectacular is happening here.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PHAR Financial Highlights

Over the last trailing twelve months PHAR reported a non-GAAP Earnings per Share(EPS) of -0.13. The EPS increased by 50% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -1.84%
ROE -3.42%
Debt/Equity 0.5
Chartmill High Growth Momentum
EPS Q2Q%175%
Sales Q2Q%25.79%
EPS 1Y (TTM)50%
Revenue 1Y (TTM)22.44%

PHAR Forecast & Estimates

14 analysts have analysed PHAR and the average price target is 18.59 USD. This implies a price increase of 29.49% is expected in the next year compared to the current price of 14.36.

For the next year, analysts expect an EPS growth of 102.62% and a revenue growth 17.66% for PHAR


Analysts
Analysts88.57
Price Target18.59 (29.46%)
EPS Next Y102.62%
Revenue Next Year17.66%

PHAR Ownership

Ownership
Inst Owners10.96%
Ins Owners1.41%
Short Float %0%
Short Ratio0.17